2,4-pyrimidinediamine compounds and their uses

US8148525B2 · kind B2 · utility

Assignee

• Rigel Pharmaceuticals, Inc. · US

Inventors

• Rajinder Singh · Belmont, US
• Ankush Argade · Foster City, US
• Donald Payan · Hillsborough, US
• Susan Molineaux · San Francisco, US
• Sasha J Holland · San Francisco, US
• Jeffrey Clough · Redwood City, US
• Holger Keim · Irvine, US
• Somasekhar Bhamidipati · Foster City, US
• Catherine Sylvain · Burlingame, US
• Hui Li · Santa Clara, US
• Alexander B. Rossi · Reedsport, US

Key dates

• Filing date: Apr 16, 2010
• Grant date: Apr 3, 2012
• Expiry date: Apr 16, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F5/027
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.